Latest issue out now. Keep up to date on the most recent regulatory changes in the world of pharma, biotech and medical device clinical trials with ICON’s Regulatory Intelligence Newsletter. Join thousands of subscribe...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
The impact of drug pricing and reimbursement on the pharmaceutical industry
Drug pricing and reimbursement constraints are a major concern for the pharmaceutical industry. Companies must consider price and reimbursement across multiple countries, act early in the development cycle and ensure the evidence required to support their commercial strategy is built into their development plans.
-
Think Tank: Mastering metrics
In this article Rebecca A Rozich, Director, Client Engagement & Medical Strategy at ICON shares how to effectively measure the true impact of campaigns across social media, disease education and marketing initiatives.
-
ICON experts tackle specialty drug access challenges at AXS24
In this article, Angela Lawrence, Senior Director of RWE, Joe Brown, Principal Medical and Market Research, and Mark McCoy, RPh, MBA, Director Market Access and Reimbursement discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.
-
Data doesn't cut it - Payer engagement requires a humanistic approach
A drug’s ability to reach the market is essential; however, pharma manufacturers have struggled to meet the increased pressure to demonstrate the value of their drugs, particularly in therapeutic areas over-populated with treatment options. Data surrounding the success and efficacy of a drug are rarely sufficient to convince stakeholders that the drug is worth the investment. Payers have displayed a need for a more humanistic approach, and against this backdrop, manufacturers need to reconsider their engagement strategies.
-
Health technology assessments: understanding the global landscape and considerations for drug development
Manpreet Sidhu and Ben Cieply share insights on how HTAs inform decisions for market access and reimbursement of new pharmacotherapies.
-
Minimising the risk of mistakes in HTA
An article in Pharmexec examining mistakes made in relation to Health Technology Assessments (HTA) and strategies to help reduce risks of future mistakes. ICON’s (ICER’s impact on payer decision making) whitepaper was referenced in the article.
-
Minimising the risk of mistakes in HTA
An article in Pharmexec examining mistakes made in relation to Health Technology Assessments (HTA) and strategies to help reduce risks of future mistakes. ICON’s (ICER’s impact on payer decision making) whitepaper was referenced in the article.
-
Pandemic priorities
The requirements for global HTA/reimbursement consideration have changed and are continuing to evolve in response to the current pandemic. This PharmaTimes article considers how drug sponsors can navigate a path to reimbursement success and market access for drugs that were in development prior to the pandemic.
